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Four distinct areas of primary sequence conservation between known tumour necrosis factor and lymphotoxin polypeptides from various species 
can be recognized. When these amino acid sequences are highlighted in the three-dimensional structure, all are found in the same region, constituting 
the framework of the trimeric structure. 
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1. INTRODUCTION 2. RESULTS AND DISCUSSION 
Tumour necrosis factor (TNF) and lymphotoxin (LT) 
are related cytokines, the former produced by activated 
macrophages or T-lymphocytes, and the latter by ac- 
tivated T-cells exclusively. Both cytokines bind to the 
same cell surface receptor and exert a wide variety of 
different biological functions. Both are believed to play 
a key role in diverse host defense mechanisms, but it is 
also recognized that they may be involved in certain 
disease states. 
The genes coding for TNF and LT of different species 
have been cloned (see [1,2] for review), allowing a 
detailed comparison of the primary sequences. As can 
be deduced from fig.1, 4 areas of higher structural 
homology can be indicated: amino acids 11-18, 48-64, 
119-133 and the 6 C-terminal residues. These regions 
encompass almost two-thirds of the conserved residues 
between TNF and LT (these 2 polypeptides are about 
30% related). On the contrary, the interspecies conser- 
vation of either TNF or LT is very high: about 80%. 
Crystals have been obtained using recombinant TNF 
from E. co/i [3,4] or S. cerevisiae [5] and recently, the 
three-dimensional structure has been elucidated at a 2.9 
A resolution [4]. TNF is a compact trimer, with 
subunits having an all-,& conformation. Each monomer 
consists of two antiparallel P-pleated sheets with the 
viral ‘jelly-roll’ motif. Here we report on the localiza- 
tion of the conserved residues between TNF and LT 
within this three-dimensional structure. 
Correspondence address: J. Tavernier, Roche Research Gent, 
Plateaustraat 35, 9000 Ghent, Belgium 
We have modelled the TNF structure using the 
published data. First, since the atomic coordinates are 
not available, by reconstructing the G-backbone, and 
followed by refinement of the model using an energy- 
minimization program [6]. When we highlight the 4 
aforementioned conserved areas on this model it is clear 
that the residues involved are mainly grouped in the in- 
ner core of the structure, suggesting a structural role 
(fig.2). Interestingly, all these residues are situated in 
the lower half of the molecule. In addition, almost all of 
the conserved residues located outside of the 4 
homology boxes are also found in this lower part. 
It is tempting to speculate on the consequences of this 
finding. The fact that almost all conserved residues 
reside in the lower half of the structure suggest a 
likewise location of the receptor binding site. Several 
data are in agreement with this hypothesis. 
(i) We have been able, by epitope mapping, to pin- 
point the residue Arg-131 as being involved in the bind- 
ing of a neutralizing monoclonal antibody directed 
against human TNF [7]. Another study showed that an- 
tibodies against a synthetic peptide spanning the N- 
terminal 15 amino acids could also neutralize the 
biological activity [S]. Both results point towards the 
lower half of the trimeric structure as being involved in 
receptor binding. In the two cases, however, the effects 
on the biological activity are most likely due to 
topological shielding of the receptor binding site by the 
antibodies. 
(ii) A single disulfide bridge between residues 69 and 
101 is located at the top of the molecule as shown in 
fig.2A. TNF variants, in which this disulfide bridge has 
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Fig. 1. Primary sequence conservation amongst TNF and LT. The complete amino acid sequences are shown of mature lymphotoxin (mouse [lo] 
and human Ill]) and tumour necrosis factor (human [12], mouse (131 and rabbit 1141). Numbering refers to the human TNF motecute. Gaps have 
been introduced to optimize alignment. Full boxes indicate conserved residues between all 5 polypeptides; dashed boxes add conservative changes. 
been removed by site-specific mutagenesis ( ubstitution 
of the Cys residues by Ser) have an only slightly reduced 
specific activity when compared to wild-type TNF ([9], 
our own unpublished data). Also, crystal analysis data 
have indicated that this upper region of the structure 
has a high main-chain mobility [4]. 
(iii) Using a random mutagenesis approach, we 
located inactivating, single amino acid mutations in 
close vicinity of the 131 Arg residue (Van Ostade, 
manuscript in preparation) suggesting that the receptor 
binding site is a constellation of residues located in the 
lower half of the TNF trimer. 
Interestingly, none of these inactivating mutations 
correspond to conserved residues between TNF and LT, 
suggesting that many of the conserved residues might 
have a mainly structural role. One explanation for the 
remarkable conservation of the core might be that this 
structure is essential in the folding process to yield the 
correct conformation, or to maintain the correct posi- 
tioning of the residues involved in receptor binding. 
Alternatively, it cannot be excluded that the conserved 
areas constitute a sofar unknown functional domain 
within the TNF molecule which perhaps is only ac- 
tivated after the internalization process. It remains in- 
triguing to know how the less conserved areas between 
TNF and LT are still responsible for binding to the 
same surface receptor. The elucidation of the structure 
of LT certainly will help to understand this. 
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Fig.2. Localization of conserved residues within the TNF structure. (A) The TNF trimer is presented with the GY backbone and side chains, and 
is shown with the 3-fold axis vertical. Highlighted in blue are the residues conserved between TNFs and LTs. The green spheres near the top show 
the positions of the disulphide bridges. (B) Same as A but the monomeric structure is shown. (C) Same as A but the view is from above. For reasons 
of clarity, two monomers are only presented with their Gr backbone (yellow). 
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